New publication from Maverex – Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review – in Respiratory Research
We are delighted to announce that our latest publication, a systematic review of the safety and efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disorder (COPD), is now available at Respiratory Research.
COPD is a leading cause of morbidity and mortality worldwide, and a recent strategy document on treatment (GOLD) recommends the use of choice of treatment is dependent on symptom and exacerbation severity. Despite this, evidence has suggested that triple therapies of a long acting β2 agonist (LABA), long acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS) are frequently over prescribed.
Sue, Jen, Nick, Nina, and Julia systematically reviewed and analysed six studies (TRINITY, TRIOLOGY, TRIBUTE, IMPACT, FULFIL, and KRONOS) which compared triple-therapy inhalers with comparators. The team then generated the first systematic and critical review of the evidence base for single inhaler triple-therapy inhalers to treat COPD and explore the differences in patient subgroups.
Key findings of the systemic review include:
- Triple therapy single inhaler significantly reduces exacerbations over dual and monotherapy comparators
- Absolute benefits are most profound in patients with preceding exacerbations, high eosinophil counts, and ex-smokers
- Some triple therapy treatment regimens result in a significantly increased risk of pneumonia
- Shortcomings of the included studies’ design and subgroup analysis
If you would like to read more, the full publication is available here.